Get started
Author

Ndapewa Ithete

Observed name: Ithete, Ndapewa
OpenAlex ID: A5094058624
Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial
2026 · Cyril Erameh, Kevin Okwaraeke, et al. · Nature Medicine · 5
Prospective cohort study to evaluate Lassa fever incidence, symptoms and coinfection with malaria in West Africa: the Enable Lassa Research Programme (‘ENABLE 1.5’) – study protocol
2025 · Henshaw Mandi, Danny Asogun, et al. · BMJ Public Health · 3
PDF
OA-652 Safety and tolerability of favipiravir for the treatment of Lassa fever: a randomized controlled open label phase II clinical trial
2023 · Mirjam Groger, Kevin Okwaraeke, et al. · 2
PDF
Incidence of symptomatic Lassa virus infection in West African countries (Enable 1.0 Lassa Research Study): a prospective, multisite, cohort study
2026 · Abdel Mecit Dicko Issifou, Akpenè Ruth Esperencia Deha, et al. · The Lancet Global Health · 1
Evaluation of candidate reference materials for the harmonization of Lassa fever serology
2026 · Emma M. Bentley, Ndapewa Ithete, et al. · Emerging Microbes & Infections · 1
Safety and tolerability of Favipiravir compared to Ribavirin for the treatment of Lassa fever: A randomized controlled open-label phase II clinical trial
2025 · Cyril Emerer, Kevin Okwaraeke, et al. · Journal of Interventional Epidemiology and Public Health · 1
PDF
Prospective cohort study to evaluate Lassa fever incidence, symptoms and coinfection with malaria in West Africa: the Enable Lassa Research Programme (‘ENABLE 1.5’) – study protocol
2026 · Ithete, Ndapewa, Williams, Margaret, et al. · UNC Libraries
Evaluation of candidate reference materials for the harmonization of Lassa fever serology
2026 · Bentley, Emma M., Ithete, Ndapewa, et al. · Figshare
Works count: 8
Citation count: 13
H-index: 2
I10-index:
Year
Topic
Type